European Commission approves Roche?s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer ? an aggressive and difficult-to-treat disease
- Approval based on the Phase III IMpassion130 study, which showed that the combination improved outcomes in people with PD-L1-positive metastatic triple-negative breast cancer